Cube Pharmaceuticals announced that the cumulative deviation value of the closing price increase of the company's stock exceeded 20% for two consecutive trading days on July 9 and July 10, which was an abnormal fluctuation. The company's 4 products have been added to the “National Essential Drug Catalogue”, but sales are affected or uncertain by factors such as policy and competition. Furthermore, the company's brainless computer interface-related business and products will not affect the performance of cooperation with Aibang Healthcare. The company currently has no undisclosed matters to remind investors to invest rationally.

Cube Pharmaceuticals announced that the cumulative deviation value of the closing price increase of the company's stock exceeded 20% for two consecutive trading days on July 9 and July 10, which was an abnormal fluctuation. The company's 4 products have been added to the “National Essential Drug Catalogue”, but sales are affected or uncertain by factors such as policy and competition. Furthermore, the company's brainless computer interface-related business and products will not affect the performance of cooperation with Aibang Healthcare. The company currently has no undisclosed matters to remind investors to invest rationally.